N | O | P

Product #


Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart

SML1428 O4I2 ≥98% (HPLC) O4I2 is a potent inducer of the Octamer-binding transcription factor 4 (Oct3/4) in various human cell lines including human fibroblasts. In principle O4I2 could be a useful tool for chemical-mediated induction of pluripotency in somatic cells.
SML2886 O4I3 ≥98% (HPLC) O4I3 is a highly potent and KDM5A (JARID1A) subtype-selective H3K4 demethylase KDM5 inhibitor (KDM5A IC50 = 0.15 nM vs KDM5B/C/D IC50 = 125.2/9.76/4.7 nM, KDM4 IC50 = 249 nM, LSD1 IC50 >100 μM) that effectively induces OCT4 expresson and improves OSKM-induced pluripotent stem cell (iPSC) reprogramming efficiency of human primary fibroblasts (50 nM) by preventing KDM5A from interfering with H3K4Me3 enrichment at the OCT4 promoter. O4I3 promotes hPSC homeostasis and represses cellular differentiation, increasing hPSCs viability up to 4-fold at a low 10 nM concentration when compared with Rock inhibitor Y-27632 treatment at 10 μM.
SML0651   OAC1 ≥98% (HPLC) OAC1 enhances iPSC reprogramming efficiency by enhancing Oct4 and Nanog driven gene expression. Treatment of mouse embryonic fibroblasts transduced with Oct2, Sox2, Klf4 and c-myc displayed a two-fold increase in the formation of ESC-like clones. OAC1 treated cells display a hypomethylated state of Oct4 promoter DNA.
SML1650 OAC2 ≥97% (HPLC) OAC2 (Oct4 activating compound 2) is an activator of Octamer-binding transcription factor 4 (Oct4), which is involved in the self-renewal of undifferentiated embryonic stem cells, regulating embryonic stem cell pluripotency.
SML2560 OB-1 ≥98% (HPLC) OB-1 is an inhibitor of the oligomerization of Stomatin-like protein-3 (STOML3), which is a modulator of the mechanosensitive ion channel Piezo2. STOML3 requires oligomerization for its role as an endogenous regulator of the sensitivity of mechanosensitive Piezo ion channels in sensory neurons. By inhibiting this activity, OB-1 has been shown to reduce touch-evoked pain behavior in two mouse models of neuropathic pain.
SML0075   OBAA ≥98% (HPLC) OBAA is a phospholipase A2 inhibitor and prevents the melittin-induced influx of Ca+2 in trypanosomes. It inhibits the generation of ROS when epithelial and endothelial cells are treated with cholic acid.
OBAA is a potent inhibitor of phospholipases.
O1877 Ochratoxin A from Petromyces albertensis, ≥98% (HPLC) Ochratoxin A is a mycotoxin found in food that is nephrotoxic and carcinogenic in the kidney and induces differentiation in cloned renal cell lines. Increases endoplasmic reticulum ATP-dependent Ca2+ pump activity.
O3007 Ochratoxin A−BSA conjugate from Aspergillus ochraceus    
O5636 9,12-Octadecadiynoic acid ≥98% Potent cyclooxygenase and lipoxygenase inhibitor.
O9262 1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine ≥99% (TLC), waxy solid Phosphoinositide-specific phospholipase C (PI-PLC) inhibitor.
O8382 17-Octadecynoic acid ≥95% (GC) 17-Octadecynoic acid (7-ODYA) is an irreversible inhibitor of cytochrome P450 isozymes, that participates in long-chain fatty acid metabolism.
Suicide substrate inhibitor that selectively and irreversibly inhibits cytochrome P450 epoxygenases and ω-hydrolases.
SML1388 N-Octanoyl dopamine ≥95% (HPLC) N-Octanoyl dopamine (NOD) protects cell cultures and tissues from cold storage inflicted damage. N-Octanoyl dopamine decreases lactate-dehydrogenase (LDH) release during cold storage of cardiomyocytes in vitro. NOD did not induce a significant elevation of intracellular cAMP and is devoid of dopaminergic and adrenergic action.
O1882 N-Octanoyl-D-sphingosine waxy solid Synthetic anaolgue of natural ceramide, activates protein kinase C, stimulates IL-2 production and induces apoptosis.
O111 Octoclothepin maleate salt solid D2 dopamine receptor antagonist; 5-HT2 serotonin receptor antagonist.
human ... DRD2(1813), HTR2A(3356), HTR2B(3357), HTR2C(3358)
SML2200 Octyl-(R)-2HG ≥98% (HPLC) Octyl-(R)-2HG (Octyl-D-2HG) is a membrane-permeant precursor form of the oncometabolite D-2-hydroxyglutarate (D-2HG) produced by tumor cells due to mutations in the NADP+-dependent isocitrate dehydrogenase genes IDH1 and IDH2. D-2HG inhibits multiple α-ketoglutarate/α-KG-dependent dioxygenases by competing against α-KG binding. Cellular D-2HG delivery by Octyl-(R)-2HG treatment (1-50 mM) is shown to suppress demethylase activity (~148% H3K9me2 and ~310% H3K79me2 upregulation; 50 mM in U-87MG) as well as increase HIF-1α and decrease endostatin levels as a result of inhibiting α-KG-dependent dioxygenases prolyl hydroxylases (PHDs) and collagen prolyl-4-hydroxylase (C-P4H), respectively.
SML2205 Octyl-α-KG ≥95% (HPLC) Octyl-α-KG (Octyl-2KG) is a membrane-permeant precursor form of α-ketoglutarate (α-KG or 2KG) whose downregulation is often seen with concomitant upreguated D-2-hydroxyglutarate (D-2HG) in tumor cells due to mutations in the NADP+-dependent isocitrate dehydrogenase genes IDH1 and IDH2, leading to reduced activity of multiple α-KG-dependent dioxygenases. Cellular α-KG delivery by Octyl-α-KG treatment (1-5 mM) is shown to restore cellular demethylase activity following octyl-2-HG (1-50 mM) treatment or IDH1(R132H) mutant expression. Octyl-α-KG also effectively reactivates α-KG-dependent dioxygenases prolyl hydroxylase (PHD) activity in cells with a dysfunctional tricarboxylic acid (TCA) cycle due to succinate dehydrogenase (SDH) and/or fumarate hydratase (FH) deficiency.
SML1836 β-ODAP ≥98% (HPLC) β-ODAP is a potent inhibitor of HIF-prolyl hydroxylase-2 (PHD-2) that induces HIF dependent HRE (hypoxia response element) in normoxic conditions. β-ODAP is an analog of glutamic acid present in Lathyrus sativus (grass pea) that activates AMPA receptors. β-ODAP causes neurolathyrism upon prolonged consumption of L. sativus seeds.
β-ODAP is considered more neurotoxic than α-ODAP, thus during food processing, its conversion to α isomer is essential. β-ODAP exhibits its neurotoxicity via the activation of metabotropic glutamatergic receptor.
SML1184 OF-1 ≥98% (HPLC) OF-1 is a chemical probe for the bromodomains of the BRPF (BRomodomain and PHD Finger containing) family of scaffolding proteins (BRPF1, BRPF2, BRPF3) that assemble histone acetyltransferase (HAT) complexes of the MYST family members MOZ and MORF. The BRPF1 protein is the scaffold subunit of the MYST acetyltransferase complex, which plays a crucial roles in DNA repair, recombination and replication as well as transcription activation. OF-1 binds to BRPF1B with a Kd of 100 nM , to BRPF2 with a Kd of 500 nM and to BRPF3 with a Kd of 2.4 mM, and shows >100-fold selectivity against most other bromodomains. The closest off-target effects are against BRD4 (39-fold selectivity) and 50% inhibition of TIF1a at 20 μM. For full characterization details, please see OF-1 on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SML1482 Ogerin ≥98% (HPLC) Ogerin is a selective positive allosteric modulator of an orphan GPCR, GPR68, also known as Ovarian cancer G-protein coupled receptor 1 (OGR1). GPR68 is one of the proton or pH-sensing GPCRs that sense extracellular H(+). Ogerin potently potentiated proton-mediated GPR68-Gs signaling. Ogerin was not active in GPR68 knockout mice, but was found to suppress recall in fear conditioning in wild-type mice, showing an unexpected effect of GPR68 on learning and memory.
SML1483 Ogerin negative control ≥98% (HPLC) Ogerin negative control is a structurally similar analog of ogerin (catalog no. SML1482). Ogerin is a selective positive allosteric modulator of an orphan GPCR, GPR68, also known as Ovarian cancer G-protein coupled receptor 1 (OGR1). GPR68 is one of the proton or pH-sensing GPCRs that sense extracellular H(+). Ogerin potently potentiated proton-mediated GPR68-Gs signaling. The meta-analog is inactive and serves as a negative control.
SML1697 OGG1 Inhibitor O8 ≥98% (HPLC) OGG1 Inhibitor O8 is a potent inhibitor of 8-Oxoguanine DNA Glycosylase-1 (OGG1), part of the DNA base excision repair (BER) pathway that is becoming a drug target for cancer therapy. OGG1 Inhibitor O8 has an IC50 value of 220 nM and >100-fold selectivity for OGG1 relative to several other DNA repair glycosylases. O8 acts through the inhibition of Schiff base formation during OGG1 catalysis. It does not prevent DNA binding of OGG1 to a 7,8-dihydro-8-oxoguanine (8-oxo-Gua)-containing substrate.
SML1383 OG-L002 hydrochloride ≥98% (HPLC) OG-L002 is a recently developed inhibitor with IC50 of 20 nM at LSD1 and much lower activity at MAO-A and MAO-B (1.38 and 0.72 μM, respectively). OG-L002 exhibits potent anti-viral activity in vitro and in mouse models of HSV infection. Lysine specific demethylase 1 (LSD1) is a histone demethylase that removes methyl groups from lysine 4 or 9 of H3 histone tails. Inhibition of LSD1 leds to suppression of herpes simplex and herpes zoster viral infections and viral reactivation from latency. MAO inhibitors (pargyline, tranylcypromine) are known to inhibit LSD1, but with low potency and selectivity. OG-L002 is a more selective and potent tool for LSD1 inhibition.
SML1209 OICR-9429 ≥98% (HPLC) OICR-9429 is a cell penetrant, potent and selective antagonist of the interaction of WDR5 (WD repeat domain 5) with peptide regions of MLL and Histone 3 that potently binds to WDR5. OICR-9429 inhibits the interaction of WDR5 with MLL1 and RbBP5 in cells. For full characterization details, please see OICR-9429 on the Structural Genomics Consortium (SGC) website.

OICR-0547 is the negative control for the active probe, OICR-9429. To request a sample of the negative control from the SGC, click here.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
O8010 Okadaic acid ammonium salt from Prorocentrum concavum ≥90% (HPLC), solid Dinoflagellate toxin and an ionophore-like polyether derivative of a 38 carbon, fatty acid. Readily enters cells. Inhibitor of type 1 and type 2A protein phosphatases. Does not inhibit tyrosine phosphatases, alkaline phosphatases or acid phosphatase. Known tumor promotor. Used to study various cellular processes including cell cycle, apoptosis, nitric oxide metabolism and calcium signaling.
O9381 Okadaic acid from Prorocentrum concavum 92-100% (HPLC) Dinoflagellate toxin and an ionophore-like polyether derivative of a 38 carbon, fatty acid. Readily enters cells. Inhibitor of type 1 and type 2A protein phosphatases. Does not inhibit tyrosine phosphatases, alkaline phosphatases or acid phosphatase. Known tumor promotor. Used to study various cellular processes including cell cycle, apoptosis, nitric oxide metabolism and calcium signaling.
O7885 Okadaic acid potassium salt from Prorocentrum concavum ≥90% (HPLC), powder Dinoflagellate toxin and an ionophore-like polyether derivative of a 38 carbon, fatty acid. Readily enters cells. Inhibitor of type 1 and type 2A protein phosphatases. Does not inhibit tyrosine phosphatases, alkaline phosphatases or acid phosphatase. Known tumor promotor. Used to study various cellular processes including cell cycle, apoptosis, nitric oxide metabolism and calcium signaling.
O7760 Okadaic acid sodium salt from Prorocentrum concavum ≥90% (HPLC), film Dinoflagellate toxin and an ionophore-like polyether derivative of a 38 carbon, fatty acid. Readily enters cells. Inhibitor of type 1 and type 2A protein phosphatases. Does not inhibit tyrosine phosphatases, alkaline phosphatases or acid phosphatase. Known tumor promotor. Used to study various cellular processes including cell cycle, apoptosis, nitric oxide metabolism and calcium signaling.
SML0933   OL-135 ≥98% (HPLC) OL-135 is a CNS penetrant, highly potent and selective reversible inhibitor of FAAH devoid of CB1, CB2 and μ and δ opioid receptors activities that increases the analgesic and hypothermic activity of anandamide.
O1141 Olanzapine ≥98% (HPLC) Olanzapine is a 5-HT2 serotonin and D1/D2 dopamine receptor antagonist.
human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2C(3358)
O2136 Oleamide ≥99% Oleamide has the ability to stimulate sleep. It possess several properties, like cannabinoid-like activity. Oleamide can also disable the communication, facilitated by gap junction between rat glial cells.
Sleep-inducing brain lipid, which allosterically modulates GABAA receptors and potentiates 5-HT7 serotonin receptor responses. Selective endogenous agonist of rat and human CB1 cannabinoid receptor.
O9762 N-Oleoylglycine ≥98% Enzymatically produced in mammals. Substrate for peptidylglycine α-amidating enzyme.
N-Oleoylglycine is equally efficient as oleamide in reducing locomotion and hypothermia.
L7260 Oleoyl-L-α-lysophosphatidic acid sodium salt ≥98%, solid Endogenous agonist for LPA1 and LPA2 receptors. LPA does not induce angiogenesis, but has effects on endothelial cell physiology that are similar to those of sphingosine 1-phosphate. Induces cell migration of cancer and non-cancer cells.
P3017 2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine ≥95.5% (GC), ≥98% (TLC) 2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine (POPC) reduces air-liquid interface associated surface tension. It is effective in alleviating alveolar collapse and pulmonary edema. POPC is typically considered one of the model lipids for biophysical experiments. It undergoes oxidative decomposition upon ozone exposure.
O9887   Oleyl trifluoromethyl ketone ≥98%, ethanol solution Inhibitor of fatty acid amide hydrolase.
O4876   Oligomycin from Streptomyces diastatochromogenes ≥90% total oligomycins basis (HPLC) Oligomycin belongs to the macrolide group of antibiotics. It inhibits mitochondrial ATP-synthase enzyme and phosphoryl group transfer. Oligomycin interacts with ATP synthase subunit-c in the Fo portion and impairs proton transport.
SML1303   Olinone ≥98% (HPLC) Olinone is a potent and selective inhibitor of BET (bromodomain and extraterminal domain) first bromodomain BrD1 that facilitates the progression of primary oligodendrocyte progenitors toward a differentiated phenotype.
SML1394 Olmesartan ≥98% (HPLC) Olmesartan is an Angiotensin II Type I receptor blocker. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil.
human ... AGTR1(185)
SML1391 Olmesartan medoxomil ≥98% (HPLC) Olmesartan medoxomil is a selective Angiotensin II Type I receptor blocker and antihypertensive drug. Olmesartan medoxomil is converted enzymatically to the active form olmesartan.
Olmesartan medoxomil is considered as an antihypertensive agent. It is an angiotensin 2 type 1 antagonist receptor. It is a prodrug which releases the parent compound olmesartan after ingestion. Olmesartan is ejected via kidney and liver. In humans, olmesartan protects renal and cardiovascular systems. This drug may be used in the treatment of hypertension.
human ... AGTR1(185)
O0886 Olomoucine ≥98% (HPLC) Olomoucine is a purine derivative which inhibits cyclin-dependent kinases and induces G arrest.
human ... CDC2(983), CDK2(1017), CDK3(1018), CDK4(1019), CDK5(1020), CDK6(1021), CDK7(1022), CDK8(1024), CDK9(1025), CDKN1A(1026), CDKN1B(1027), CDKN1C(1028), CDKN2A(1029), CDKN2B(1030), CDKN2C(1031), CDKN2D(1032), CDKN3(1033)
rat ... Prkca(24680)
O0391 Olopatadine hydrochloride ≥98% (HPLC) Olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer. The low level of occupancy H1 receptors in the brain explains the low sedation effect of olopatidine. It is believed that olopatidine is a substrate for P-glycoprotein, which limits its brain penetration.
human ... HRH1(3269)
O7389 Olprinone hydrochloride ≥98% (HPLC), solid Selective phosphodiesterase 3 (PDE3) inhibitor.
O9389 Oltipraz ≥98% (HPLC), powder Oltipraz is an activator of Nrf2. Nrf2 (NF-E2-related factor 2) is a transcription factor that binds to antioxidant response elements (AREs) and activates these genes. Oltipraz activates Nrf2 and subsequently elevates expression of the detoxification genes encoding anti-oxidant and multidrug resistance-associated proteins to mediate its chemopreventive efficacy.
SML0777   Oltipraz metabolite M2 ≥98% (HPLC) M2 is a metabolite of the chemopreventive agent oltipraz. Oltipraz metabolite M2 has been shown to inhibit liver steatosis by inhibiting lipogenesis and enhancing mitochondrial function, including fuel oxidation. Oltipraz metabolite M2 acts as a potent inhibitor of LXRa transcriptional activity, and also AMPK activator inducing the phosphorylation of AMPK.
O0257 Olvanil powder Vanilloid receptor agonist
human ... TRPV1(7442)
O8140 OM137 ≥95% (NMR) OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint. OM137 is an aminothiazole derivative, which functions to override the spindle checkpoint primarily through inhibition of the Aurora kinases (mitotic kinases). OM137 is a more potent inhibitor of Aurora B compared with Aurora A in vitro, consistent with the effects of OM137 on checkpoint function in living cells. The compound has some CDK1 inhibitory activity, but is likely that the major mode by which OM137 drives mitotic exit of cells arrested in M phase via the spindle checkpoint is through its inhibitory activity against Aurora B kinase. The compound is less potent than N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride (Sigma Cat. D6068), which is more suited for in vitro testing due to low solubility and high serum binding. OM137 is less potent than selective Aurora A inhibitor, cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide (Sigma Cat. C2368).
SML1549   Ombrabulin hydrochloride ≥98% (HPLC) Ombrabulin is a synthetic water-soluble combretastatin analog vascular disrupting agent. Ombrabulin is a tubulin polymerization inhibitor. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells.
Ombrabulin leads to the constriction of the arteries, inhibits cell proliferation and causes detachment of endothelial cells, thereby leading to cytotoxicity. In pre-clinical studies, this compound, along with cisplatin, has shown anti-tumor activity. In tumors, it is responsible for the destruction of the vasculature.
O2389 OMDM-1 ≥97% (HPLC), powder Potent, selective inhibitor of anadamide cellular uptake with low affinity for CB1 and CB2 receptors, no activity at VR1 receptor or fatty acid amide hydrolase (FAAH); stable to enzymatic hydrolysis by rat brain homogenates.
O104 Omeprazole solid Omeprazole binds covalently to proton pump (H+, K+-ATPase) and inhibits gastric secretion. It is useful in ameliorating the effects of peptic oesophagitis, duodenal and gastric ulcer. Omeprazole is preferred over antagonists of histamine H2-receptor and ranitidine for its higher efficiency. It is also useful in treating Zollinger-Ellison syndrome.
human ... ABCB1(5243), ATP4A(495), ATP4B(496), CYP1A2(1544)
O0516 Oncrasin-1 ≥98% (HPLC) Oncrasin-1 is a suppressor of RNA processing machinery. Oncrasin-1 induces aggregation of PKCL in the nuclei and is proapoptotic.
SML2896 ONO-2506 ≥98% (HPLC) ONO-2506 (arundic acid; (R)-2-propyloctanoic acid) is an inhibitory astrocytes-modulating agent that exerts glioprotective effects against amyloid-β-peptide (Aβ)-induced glial death in astrocyte cultures (50 μM ONO-2506 against 200 μM Aβ25-35, 24 hr; 1321N1 astrocytes) by decreasing both the intracellular and extracellular S100B levels. Blockade of astrocytic activation by ONO-2506 in vivo is shown to offer therapeutic efficacy in animal models of normal tension glaucoma (10 mg/kg po. mice), spinal cord injury (20 mg/kg/d ip or iv rats), brain seizure, ischemic stroke (10 mg/kg/d ip or iv rats), and Parkinson′s disease (30 mg/kg ip mice).
SML2076 ONO-AE3-208 ≥98% (HPLC) ONO-AE3-208 is an orally active prostaglandin E2 receptor 4 (EP4)-selective antagonist (Ki in nM = 1.3/EP4, 30/EP3, 790/FP and 2400/TP; Ki >10 μM for prostanoid receptors DP, EP1, EP2, IP). Both EP4-/- mice and ONO-AE3-208-treated wild-type mice (10 mg/kg/day in drinking water) are shown to develop severe symptoms (diarrhea, hemoccult, weight loss) in a murine model of DSS-induced colitis. ONO-AE3-208 is also reported to promote ductus arteriosus constriction among fetal and neonatal rats in vivo (10 mg/kg administered orogastrically). In addition, ONO-AE3-208 is demonstrated to effectively inhibit 1 ng/mL IL-1β-induced HUVEC migration in vitro (53% and 75% inhibition by 1 or 10 μM AE3-208, repectively) and block IL-1β (30 ng/Hydron pellet implant)-induced angionesis in mouse corneas in vivo (1 mg/kg/day p.o.).
O0766   ONO-RS-082 ≥97% (HPLC) ONO-RS-082 is a reversible phospholipase A2 inhibitor.
O1016 OPC-21268 hydrate ≥98% (HPLC) OPC-21268 is one of 2 non-peptide V1a selective antagonists, along with SR-49059. Arginine vasopressin (AVP) is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes-V1a, V1b, and V2 - all belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.
O1266 OPC 31260 hydrochloride ≥98% (HPLC) OPC 31260 is a vasopressin V2 selective antagonist. Arginine vasopressin (AVP) plays an important part in circulatory and water homeostasis. The V2 receptor subtype is important in water retention, cardiac remodeling in congestive heart failure (CHF), and renal hemodynamic alterations, and is considered a target for polysystic kidney disease. OPC-31260 has been shown to inhibit the development of polycystic kidney disease in several animal models.
SML1478 Ophiobolin A ≥95% (HPLC) Ophiobolin A is a fungal metabolite, toxic to many crops and found to have antimicrobial and anticancer activity. Ophiobolin A is a calmodulin antagonist and inhibitor of big conductance Ca2+-activated K+ channel (BKCa) activity. Its anticancer activity may involve inhibition of multiple oncogenic signaling pathways including PI3K/mTOR, Ras/Raf/ERK and CDK/RB. One study suggested the possibility of pyrrolylation of lysine residues on its intracellular target protein(s) as a mechanism of action on various targets.
SML1288 Ophiopogonin D ≥98% (HPLC) In rat cardiomyocytes, ophiopogonin D regulates Ca2+ homeostasis in vitro. OPD acts as an antioxidant against H2O2-stimulated endothelial injury. It possesses mild anti-apoptotic properties. It plays a protective role in doxycycline (DOX)-stimulated autophagy in cardiomyocytes.
Ophiopogonin D is a steroidal glycoside extracted from Ophiopogon japonicas that promotes antioxidative protection of the cardiovascular system. Ophiopogonin D protects the heart against doxorubicin-induced autophagic injury by reduction of both ROS generation and the disruption of the mitochondrial membrane damage.
O5889 Opipramol dihydrochloride ≥98% (HPLC), solid σ12 opioid receptor agonist; an antagonist at D2, 5HT2 and H1 receptors; atypical antidepressant, antipsychotic and anxiolytic
O7639 Org 24598 lithium salt ≥98% (HPLC), solid Org 24598 is a selective, potent inhibitor of glial GlyT (GlyT1, glycine transporter type 1). In rats (P12-P16) and in the presence of kynurenic acid, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and bicuculline, ORG 24598 at a concentration of 10 μM induced a mean inward current of -10/-50 pA at -60 mV and increased significantly the decay time constants of miniature (mIPSCs), spontaneous (sIPSCs) and electrically evoked glycinergic (eIPSCs) inhibitory postsynaptic currents. Replacing extracellular sodium with N-methyl-d-glucamine or superfusing the slice with micromolar concentrations of glycine also increased the decay time constant of glycinergic IPSCs. Glycine (1-5 μM and d-serine (10 μM) increased the amplitude of eEPSCs whereas l-serine had no effect. Org 24598 increased significantly the amplitude of NMDA receptor-mediated eEPSCs without affecting the amplitude of non-NMDA receptor-mediated eEPSCs. This brings conclusion that blocking glial glycine transporter by Org 24598 increased the level of glycine in spinal cord slices, which in turn prolonged the duration of glycinergic synaptic current and potentiated the NMDA-mediated synaptic response.
SML2417 ORG 25543 Hydrochloride ≥95% (HPLC) ORG 25543 is a brain-penetrant (free brain/plasma ratio = 0.53; 35 min post 2 or 20 mg/kg i.v. in mice), high-affinity, potent and selective glycine transporter 2 (GlyT-2; GlyT2) inhibitor (human & mouse pIC50 = 7.9/ GlyT2 vs <4/GlyT1) with great selectivity over a panel of 56 receptor and channel proteins. ORG 25543 is more potent and selective than the brain-impermeable ALX-1393 (GlyT2/GlyT1 pIC50 = 7.1/5.4) and exhibits high in vivo efficacy in a murine diabetic neuropathic pain model (ED50 = 0.07-0.16 mg/kg i.v.; Emin = 0.01 mg/kg). ORG 25543 is practically irreversible due to its tight-binding nature, suboptimal dosage should be applied in vivo to allow low target occupancy only and minimize acute toxicity.
O9639 Oridonin ≥98% (HPLC), solid Oridonin has potent anti-tumor activity. Oridonin targets AE (AML1-ETO) oncoprotein. Exposure to oridonin induces apoptosis in AE-bearing leukemic cells through the activation of intrinsic apoptotic pathway and triggering a caspase-3-mediated degradation of AE at D188. The compound also prolonged the lifespan of C57 mice bearing truncated AE-expressing leukemic cells without side effects like suppression of bone marrow or reduction of body weight of animals, and exerted synergic effects while combined with cytosine arabinoside. Additionally, oridonin inhibited tumor growth in nude mice inoculated with t(8;21)-harboring Kasumi-1 cells.
SML1586   Oritavancin diphosphate ≥97% (HPLC) Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.
O4139 Orlistat ≥98%, solid Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis.
Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.
human ... LIPF(8513), PNLIP(5406)
SML0972   ORM-10103 ≥98% (HPLC) ORM-10103 is a potent, specific inhibitor of the Na(+)/Ca(2+) exchanger, NCX. The compound ORM-10103 inhibits both inward and outward NCX currents with IC50 values of 780 nM, and 960 nM, respectively. ORM-10103 blocks induced arrhythmias in canine cardiac tissue.
SML1872 ORM-3819 ≥98% (HPLC) ORM-3819 is a potent inotropic agent that binds to cardiac troponin C (cTnC) and sensitizes heart to Ca2+. Also, ORM-3819 is a selective and potent inhibitor of PDE III. ORM-3819 exhibits positive inotropic effects through Ca2+-sensitization and selective inhibition of PDE III. ORM-3819 was effective in vivo dog model of myocardial stunning.
SML2237 Ormeloxifene ≥95% (HPLC) Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
SML2320 Ornipressin acetate salt ≥98% (HPLC) Ornipressin is a potent vasoconstrictor agent used in surgery for hemostasis and in regional anesthesia for prolongation of nerve block. Ornipressin is a vasopressin agonist specific for the V1 receptor with low antidiuretic activity.
SML1015   OS-3-106 ≥98% (HPLC) OS-3-106 is a potent and selective dopamine D3 receptor (D3R) partial agonist that blocked a D3R-mediated behavior in rats. OS-3-106 is effective in reducing cocaine self-administration.
SML0798   Osanetant ≥98% (HPLC) Osanetant is a selective antagonist of neurokinin 3 receptor NK3. Neurokinins (tachykinins) are members of a family of at least three neuropeptides, substance P, neurokinin A, and neurokinin B (NKB), with each mediating their biological effects through binding to a preferred G-protein-coupled receptor termed NK1, NK2, or NK3, respectively. All three NK receptors are expressed in regions of the central nervous system that are related to emotion and cognition (i.e., amygdala and hippocampus) and have been linked to various degrees in psychiatric disorders. Neurokinin receptors, including NK3 receptors, are also expressed in the motor and sensory systems of the digestive tract. Osanetant was in clinical trials for both irritable bowel syndrome and schizophrenia.
SML1606 Oseltamivir phosphate ≥98% (HPLC) Oseltamivir phosphate is an influenza viral neuraminidase inhititor. Oseltamivir phosphate, an antiviral, is used clinically to treat influenza A and influenza B, and to prevent flu after exposure. Oseltamivir phosphate is hydrolyzed in the liver to its active form, oseltamivir carboxylate, which is an inhibitor of influenza viral neuraminidases essential for viral replication. Oseltamivir has a broad spectrum of activity against a range of influenza A and B subtypes with IC50 values for neuraminidases measured from less than 1 nM to approximately 30 nM, depending on the virus subtype.
SML1621 OSMI-1 ≥98% (HPLC) OGT catalyses the attachment of N-acetylglucosamine moieties to a number proteins during post-translational modification. Inhibition of OGT activity might hinder the rate of viral replication in infections such as Herpes simplex viral disease.
OSMI-1 is a cell permeable inhibitor of OGT (O-GlcNAc transferase).
SML0996   Ospemifene ≥98% (HPLC) Ospemifene is a selective estrogen receptor modulator (SERM), a metabolite of toremifene, with a unique estrogen agonist/antagonist tissue profile. Ospemifene was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women, and is being investigated for the treatment and prevention of osteoporosis and breast cancer. Ospemifene binds ERα and ERβ with approximately equal affinities with IC50 values for estrogen receptor (ER) α and β of 0.8 μM and 1.7 μM, respectively. Ospemifene has estrogen-like effects on the vaginal epithelium and bone, antiproliferative effects in breast, and a neutral endometrial profile.
PZ0177 OSU6162 hydrochloride ≥98% (HPLC) OSU6162 (PNU-96391) is a dopamine stabilizer, a drug that can stimulate or inhibit dopaminergic signaling depending on the dopaminergic tone. Dopaminergic stabilizers have been proposed to act as partial dopamine receptor agonists or as antagonists with both dopamine and behavioral stabilizing activity. Although affinity is not high (in vitro binding affinity for dopamine D2 receptor has a Ki of 447 nM), OSU6162 shows a high level of receptor occupancy.
SML1454 Otilonium bromide ≥98% (HPLC) Otilonium Bromide is a muscarinic receptor antagonist (antimuscarinic). Otilonium Bromide is a quaternary ammonium salt that exerts spasmolytic action selective on the distal gastrointestinal tract. It is used world-wide for the treatment of irritable bowel syndrome (IBS).
Otilonium bromide has the capability to prevent L-type Ca2+ channels and colonic contractile activity. It is a tolerable drug as it is absorbed poorly and has very less side effects.
SML1605 OTX015 ≥98% (HPLC) It binds to bromodomain and extra-terminal domain (BET) proteins and inhibits their binding to the chromatin. This in turn prevents gene transcription. OTX015 has been shown to inhibit proliferation of cells in haematological malignancies.
OTX015 is a potent inhibitor of the BET bromodomain proteins 2, 3, and 4 (BRD2/3/4).
human ... BRD2(6046), BRD3(8019), BRD4(23476), BRDT(676)
O3125 Ouabain octahydrate ≥95% (HPLC), powder Cardiac glycoside, inhibits Na(+)/K(+) ATPase, regulates transcription of MDR (increase, Pgp) and MRP (increase MRP1 and decrease CFTR, cyctic fibrosis transport receptor or cAMP-activated Cl- channel) genes, also alters localization of MRP1. Ouabain resistance is associated with appearance of Na(+)/K(+) ATPase isoforms with low binding affinity.
Ouabain has its specific binding site on integral proteins of the plasma membrane. Heart disease is treated using ouabain derivatives. Increased ouabain production is observed during exercise in humans. Abnormally high levels of ouabain are indicated in congestive heart failure and hypertension. Ouabain signalling affects intracellular calcium levels, which is known to activate nuclear factor κB (NFκB).
human ... ATIC(471)
rat ... Atp1b1(25650)
SML1864 OUL35 ≥98% (HPLC) OUL35 is a cell penetrant, potent and selective ARTD10/PARP10 inhibitor. OUL35 rescues HeLa cells from ARTD10 induced apoptotic cell death.
S7951 Ovalbumin (257-264) chicken ≥97% (HPLC) Ovalbumin (257-264) chicken is an antigenic peptide and triggers immune response. Administration of the ovalbumin peptide in pregnant mice helps in surpassing ear development anomalies.
SIINFEKL is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA); the ovalbumin fragment is presented by the class I MHC molecule, H-2Kb.
SML2072   OX03050 ≥98% (HPLC) OX03050 is a metabolically stable, potent and selective squalene synthase inhibitor that upregulates the Low-Density Lipoprotein Receptor (LDLR) in mouse and in human liver cell lines. OX03050 used in conjunction with statin acts synergistically to increase LDLR expression
O9512 Oxaliplatin powder Oxaliplatin a platinum analogue, causes DNA damage and cell death by binding to DNA and forming inter and intrastrand crosslinks preventing replication and transcription. Oxaliplatin is an anti-tumor agent with activity against colorectal cancer; cytotoxicity follows the formation of adducts with DNA. Oxaliplatin is an approved drug for treating colorectal cancer. It is an active ingredient in FOLFOX (Folinic acid:5-FU:oxaliplatin in the ratio 1:10:1 of micromolar concentrations respectively). Oxaliplatin causes both acute and chronic neurotoxicity in patients in a dose dependent manner and is reversible either by reducing or stopping the drug.
O9390 N-Oxalylglycine ≥98% (HPLC) N-Oxalylglycine is an inhibitor of α-ketoglutarate-dependent enzymes and mimics the initial steps but does not initiate the hydroxylation process. N-Oxalylglycine has been used to inhibit Jumonji C-domain-containing histone lysine demethylases.
O3139 Oxamflatin ≥98% (HPLC), solid Histone deacetylase inhibitor; anti-cancer agent.
PZ0393 Oxamniquine ≥98% (HPLC) Oxamniquine is an anthelmintic agent with schistosomicidal activity against Schistosoma mansoni.
SML0437 Oxandrolone ≥98% (HPLC) Oxandrolone is a synthetic anabolic steroid. It is is a non-aromatizable androgen with no estrogenic effects and with mild androgenic activity. Clinical uses of oxandrolone include to promote weight gain after weight loss following extensive surgery or chronic infections or trauma, to offset the protein catabolism associated with prolonged administration of corticosteroids, to relieve bone pain frequently accompanying osteoporosis, and to treat Turner′s syndrome in girls.
human ... AR(367)
SML2469 Oxanthroquinone G01 ≥98% (HPLC) Oxanthroquinone G01 is a potent inhibitor of KRAS and NRAS plasma membrane localization that potently inhibits proliferation of KRAS transformed cancer cells. Oxanthroquinone G01 also inhibits recycling of epidermal growth factor receptor and transferrin receptor, but has no influence on cholera toxin internalization. It also increases cellular levels of sphingomyelin and and ceramide.
SML2309 Oxaphenamide ≥98% (HPLC) Osalmid is a potent inhibitor of ribonucleotide reductase small subunit M2 (RRM2) that potently inhibits HBV DNA and cccDNA synthesis in HepG2.2.15 cells. Osalmid inhibits RR (ribonucleotide reductase) activity in vivo, and exhibits synergistic effect with lamivudine on inactivation mutant HBV strain. Osalmid is a biliation activator (choleretic agent), but a mechanism of this activity remains unknown.
O9637 Oxaprozin solid   human ... PTGIR(5739), PTGS1(5742), PTGS2(5743)
O9387   Oxatomide ≥99% Oxatomide is an anti-allergy compound, H1 receptor antagonist. Oxatomide suppresses PAF-induced bronchoconstriction; inhibits leukotriene production.
human ... DRD3(1814)
O5254 Oxazepam Anxiolytic; ligand for the GABAA receptor benzodiazepine modulatory site.
human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)
SML1792 Oxazole yellow ≥98% (HPLC) Oxazole yellow is a fluorescent cyanine dye that binds to DNA and is used to detect apoptotic cells. Oxazole yellow does not enter live cells. However, during apoptosis the cytoplasmic membrane becomes slightly permeable, allowing entry of the dye. Oxazole yellow is often used along with propidium iodide (catalog no. P4170), a DNA dead cell stain that does not enter either live or apoptotic cells. The λEx/λEm of Oxazole yellow is 491/509.
ALD00032 1-(Oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one    
O3764 Oxcarbazepine ≥98% (HPLC), solid Anticonvulsant, antineuralgic. Inhibits veratrine-induced transmitter release.
human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scnn1g(24768)
SML2466 OXFBD04 ≥98% (HPLC) OXFBD04 is a potent and selective inhibitor of BRD4(1) that inhibits interactions of BRD4with the RelA subunit of NF-κB. OXFBD02 inhibits proliferation of various cancer cell lines including leukaemia, breast, and renal cancer cell lines.
SML1474   Oxiconazole nitrate ≥98% (HPLC) Oxiconazole is a broad-spectrum antifungal agent that inhibits ergosterol biosynthesis. Oxiconazole destabilizes Lanosterol 14-α demethylase (fungal cyctochrome P450 51).
UC167 Oxidized Nifedipine powder, ~95% (HPLC) CYP3A4 nifedipine metabolite. Nifedipine (parent compound) is an antianginal and antihypertensive agent.
Nifedipine is a dihydropyridine derivative and a calcium channel blocker. It is used in treating hypertension and angina pectoris. Oxidized Nifedipine is an oxidation product of nifedipine generated either by exposure to UV or day light. The enzyme cytochrome P450 3A (CYP3A4) metabolizes nifedipine.
O2757 3-Oxo-4-aza-5α-androstane-17β-(N-t-butylcarboxamide) ≥90%, powder    
SML0984 7-Oxostaurosporine ≥98% (HPLC)    
O9126 Oxotremorine sesquifumarate salt ≥98% (HPLC), solid Oxotremorine sesquifumarate salt is a muscarinic acetylcholine receptor agonist with preference for the M2 receptor.
human ... CHRM2(1129)
O100 Oxotremorine M solid Nonselective muscarinic acetylcholine receptor agonist.
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
O9890 5Z-7-Oxozeaenol ≥98% (HPLC) 5Z-7-oxozeaenol is a potent ATP-competitive irreversible inhibitor of ERK2 (IC50 = 80 nM), TAK1 (MEKK7), MKK7, and MEK1, which all contain a common cysteine residue in the ATP-binding site. 5Z-7-oxozeaenol has no activity against other MAP kinases. 5Z-7-oxozeaenol is also anti-inflammatory.
The anti-inflammatory effects of 5Z-7-oxozeaenol may affect cardiac hypertrophy.
O2881 Oxybutynin chloride ≥98% (TLC), powder Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
O2378 Oxymetazoline hydrochloride ≥99%, solid Oxymetazoline hydrochloride is a partial α2A-adrenoceptor agonist; agonist at 5-HT1A, 5-HT1B, and 5-HT1D serotonin receptors. It is a mixed agonist-antagonist at 5-HT1C serotonin receptors.
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), HTR1A(3350), HTR1B(3351), HTR1D(3352)
SML0540   Oxyphenbutazone ≥98% (HPLC) Oxyphenbutazone is a non-steroid anti inflammatory; anti Mycobacterium tuberculosis agent. Oxyphenbutazone is known to cause inflammatory effects on tissues. Oxyphenbutazone, as a drug, decreases cellular exudates, without involving the pituitary-adrenal axis or the immunity response. Though the drug delivers a number of side effects, it is considered to be less toxic than phenylbutazone, due to decreased rate of intestinal absorption.
Oxyphenbutazone is an NSAID that has been shown to preferentially kill non-replicating Mycobaterium tuberculosis maintained in media that simulates the mildly acidic, in vivo conditions where drug-resistant, non replicating subpopulations of the bacteria reside in hosts. The compound has little or no affect on replication M. tuberculosis grown in normal liquid cultures.
O1385 Ozagrel hydrochloride hydrate ≥98% (HPLC), solid Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.